Literature DB >> 31129247

LncRNA TP73-AS1 is upregulated in non-small cell lung cancer and predicts poor survival.

Dapeng Zhu1, Jiaming Zhou2, Yuanshun Liu2, Lingbin Du3, Zhiguo Zheng4, Xiang Qian5.   

Abstract

The present study was carried out to investigate the role of lncRNA TP73-AS1 in non-small cell lung cancer (NSCLC). We found that TP73-AS1 was upregulated in tumor tissues than in non-tumor tissues of NSCLC patients, and high expression levels of TP73-AS1 predicted poor survival. MiR-21 was also upregulated in tumor tissues and positively correlated with TP73-AS1. TP73-AS1 overexpression led to miR-21 upregulation, while miR-21 overexpression failed to affect TP73-AS1. TP73-AS1 and miR-21 overexpression caused the accelerated invasion and migration of NSCLC cells. However, TP73-AS1 overexpression failed to affect cell proliferation. Therefore, TP73-AS1 may upregulate miR-21 to promote NSCLC cell migration and invasion.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Non-small cell lung cancer; Survival; lncRNA TP73-AS1; miR-21

Mesh：

Substances：

Year:  2019        PMID： 31129247     DOI： 10.1016/j.gene.2019.05.044

Source DB:  PubMed          Journal:  Gene        ISSN： 0378-1119            Impact factor:   3.688


  9 in total

1.  TP73-AS1 as a predictor of clinicopathological parameters and prognosis in human malignancies: a meta and bioinformatics analysis.

Authors:  Caizhi Chen; Jingjing Wang; Yeqian Feng; Ye Liang; Yan Huang; Wen Zou
Journal:  BMC Cancer       Date:  2022-05-25       Impact factor: 4.638

2.  Long Non-Coding RNA TP73-AS1 Promotes the Development of Lung Cancer by Targeting the miR-27b-3p/LAPTM4B Axis.

Authors:  Qingfeng Jiang; Wenqun Xing; Jinhua Cheng; Yongkui Yu
Journal:  Onco Targets Ther       Date:  2020-07-20       Impact factor: 4.147

Review 3.  Long Non-coding RNAs in Myeloid Malignancies.

Authors:  Alina-Andreea Zimta; Ciprian Tomuleasa; Iman Sahnoune; George A Calin; Ioana Berindan-Neagoe
Journal:  Front Oncol       Date:  2019-10-18       Impact factor: 6.244

4.  Knockdown Of Long Non-Coding RNA TP73-AS1 Inhibited Cell Proliferation And Metastasis Through Wnt/β-Catenin Pathway In Lung Adenocarcinoma.

Authors:  Ying Peng; Yan Xu; Guangming Yang; Shiwei Li; Zhilian Rui
Journal:  Onco Targets Ther       Date:  2019-11-13       Impact factor: 4.147

5.  DNA Methylation Activates TP73 Expression in Hepatocellular Carcinoma and Gastrointestinal Cancer.

Authors:  Zhixing Yao; Cristina Di Poto; Grace Mavodza; Everett Oliver; Habtom W Ressom; Zaki A Sherif
Journal:  Sci Rep       Date:  2019-12-18       Impact factor: 4.379

6.  Long non‑coding RNA TP73‑AS1 accelerates the progression and cisplatin resistance of non‑small cell lung cancer by upregulating the expression of TRIM29 via competitively targeting microRNA‑34a‑5p.

Authors:  Shunxiang Luo; Ming Shen; Hui Chen; Weiwei Li; Cong Chen
Journal:  Mol Med Rep       Date:  2020-09-01       Impact factor: 2.952

7.  LncRNA TP73-AS1 Exacerbates the Non-Small-Cell Lung Cancer (NSCLC) Process via Regulating miR-125a-3p-Mediated ACTN4.

Authors:  Yueyang Tong; Zhemin Feng; Yaqian Li; Chenxi Yan; Wenbo He; Xueyuan Chen
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-09       Impact factor: 2.650

8.  Long Noncoding RNA PTPRG Antisense RNA 1 Reduces Radiosensitivity of Nonsmall Cell Lung Cancer Cells Via Regulating MiR-200c-3p/TCF4.

Authors:  Qiang Ma; Rungui Niu; Wei Huang; Liangshan Da; Yanlei Tang; Daowen Jiang; Yanfeng Xi; Congjun Zhang
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

9.  A Signature of 14 Long Non-Coding RNAs (lncRNAs) as a Step towards Precision Diagnosis for NSCLC.

Authors:  Anetta Sulewska; Jacek Niklinski; Radoslaw Charkiewicz; Piotr Karabowicz; Przemyslaw Biecek; Hubert Baniecki; Oksana Kowalczuk; Miroslaw Kozlowski; Patrycja Modzelewska; Piotr Majewski; Elzbieta Tryniszewska; Joanna Reszec; Zofia Dzieciol-Anikiej; Cezary Piwkowski; Robert Gryczka; Rodryg Ramlau
Journal:  Cancers (Basel)       Date:  2022-01-16       Impact factor: 6.639
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.